Phase III Clinical Trial – Novartis
A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa
To participate in your local study, please contact (949) 707-5734 or fill out the form below.
CAIN457M2302
Lorem ipsum dolor sit amet, consectetur adiop iscing elit, sed do eiusmod tempor inci didunt ult labore et dolore magna aliqua.